Communiqués Avenue Therapeutics, Inc.

Actions

ATXI

US05360L4032

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 17:30:40 04/06/2026			Varia. 5j.	Varia. 1 janv.
0,4400 ^USD	+46,67%		+62,96%	-35,31%

07/08	Avenue Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
08/05	Avenue Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

14/11/24	Avenue Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K	PU
14/11/24	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
09/10/24	Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit	AQ
03/09/24	Avenue Therapeutics to Participate in Upcoming Investor Conferences	AQ
12/08/24	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
09/08/24	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
20/06/24	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	AQ
16/05/24	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	AQ
15/05/24	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
13/05/24	Avenue Therapeutics : Material Agreement - Form 8-K	PU
26/03/24	Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	AQ
25/03/24	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	AQ
18/03/24	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	AQ
15/03/24	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	AQ
11/03/24	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	AQ
22/02/24	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	AQ
11/01/24	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	AQ
05/01/24	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	AQ
04/01/24	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	AQ
03/01/24	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	AQ
02/01/24	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	AQ
04/12/23	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	AQ
01/12/23	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	AQ
13/11/23	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	AQ
02/11/23	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering	AQ